Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIUPRES-500 vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Essential hypertension,Edema associated with congestive heart failure, hepatic cirrhosis, and renal dysfunction
Hypertension
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Chlorothiazide is not metabolized and is excreted unchanged in urine. Reserpine is extensively metabolized in the liver via CYP450 enzymes to inactive metabolites.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Reserpine: ~96% (albumin). Hydrochlorothiazide: ~68% (albumin).
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Reserpine: 4-8 L/kg (extensive tissue binding, especially lipid-rich and CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: Reserpine ~50% (variable due to first-pass metabolism); Hydrochlorothiazide ~65-70% (dose-dependent).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
GFR 30-50 m L/min: use with caution, reduce dose if needed. GFR <30 m L/min: contraindicated.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: contraindicated due to risk of hepatic encephalopathy.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate at lowest dose (50 mg hydrochlorothiazide + 0.125 mg reserpine) once daily; monitor electrolytes, renal function, and CNS depression.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Electrolyte imbalance: Monitor potassium, sodium, magnesium; hypokalemia increases risk of digitalis toxicity,Mental depression: Reserpine may cause severe depression, especially in patients with history,Sulfonamide cross-sensitivity: Chlorothiazide may cause allergic reactions in patients with sulfonamide allergy,Azotemia: May precipitate renal impairment in patients with kidney disease,Orthostatic hypotension: Common with reserpine, especially after initial doses
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to chlorothiazide, reserpine, or sulfonamide-derived drugs,Anuria,Active peptic ulcer disease,Ulcerative colitis,History of mental depression (especially with suicidal tendencies),Electroconvulsive therapy,Pheochromocytoma
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, spinach) due to increased potassium retention risk with hydrochlorothiazide. Limit alcohol consumption as it may enhance blood pressure-lowering effects and cause dizziness. Maintain adequate hydration but avoid potassium-containing salt substitutes.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Risk of fetal hydantoin syndrome (craniofacial defects, hypoplastic nails, growth deficiency). Second trimester: Increased risk of neural tube defects, congenital heart defects. Third trimester: Risk of neonatal hemorrhage and hepatic enzyme induction.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excreted in breast milk; M/P ratio approximately 0.2-0.4. Consider risk of infant sedation and poor feeding. Weigh benefits of breastfeeding against potential adverse effects.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Increased clearance due to hepatic induction and increased volume of distribution; may require up to 50% dose increase. Monitor free phenytoin levels as protein binding decreases. Adjust dose to maintain therapeutic levels.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
DIUPRES-500 contains hydrochlorothiazide 50 mg and reserpine 0.125 mg. Monitor serum potassium and renal function regularly. Reserpine may cause bradycardia and depression; use with caution in patients with history of peptic ulcer disease. Avoid abrupt discontinuation due to risk of withdrawal hypertension.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed, usually once daily in the morning.,Do not stop taking this medication suddenly without consulting your doctor.,This drug may make you urinate more frequently; avoid taking it before bedtime.,Report any symptoms of depression, unusual fatigue, or slow heart rate to your doctor.,Avoid prolonged sun exposure and use sunscreen; this medication can increase sensitivity to sunlight.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIUPRES-500 vs ALDORIL D30, answered by our medical review team.
DIUPRES-500 is a Antihypertensive Combination that works by Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIUPRES-500 and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIUPRES-500 is: Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIUPRES-500 and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIUPRES-500 is classified as Category C. First trimester: Risk of fetal hydantoin syndrome (craniofacial defects, hypoplastic nails, growth deficiency). Second trimester: Increased risk of neural tube defects, congenital . ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.